Gene Express Enters Into India Distribution Agreement With Biogenuix Medsystems Pvt. Ltd.

WILMINGTON, NC--(Marketwire - January 22, 2009) -

Highlighted Links

Gene Express Inc.

Biogenuix

Gene Express Inc. announced today that it has entered into a Distribution Agreement with Biogenuix Medsystems Pvt. Ltd. for the distribution of Gene Express Inc's Standardized RT-PCR reagents (StaRT-PCR™) and research molecular diagnostic tools. The non-exclusive agreement provides Biogenuix with the rights to distribute in India.

Jonathan Rowe PhD, Chief Operating Officer for Gene Express Inc., stated, "This will be the first time that Gene Express' patented standardized gene expression technology will be made widely available to Indian researchers. By partnering with a valuable partner in Biogenuix, we are confident that the Gene Express tests and reagents will be widely accepted in the Indian research market."

Sundeep Amar, Director of Biogenuix Medsystems Pvt. Ltd., stated, "We are very optimistic about the potential of StaRT-PCR™ in India. This is the right time to enter the Indian molecular diagnostic & research market as there is a rapid growth in the installation base of RT-PCR platforms in the country."

Among the StaRT-PCR™ based research molecular tools are kits for Chronic Myelogenous Leukemia (bcr-abl), Lung Cancer Risk Prediction and Inflammation/Rheumatoid Arthritis. The reagents include a selection of more than six hundred StaRT-PCR™ internal standards.

About Biogenuix Medsystems Pvt. Ltd.

Biogenuix plays a key role as a marketer, market research & service provider to scientific & healthcare companies and professionals by offering unique solutions through its philosophy of innovation, quality, dependability and consistency. Biogenuix has long-term distribution and marketing agreements with more than 20 leading manufacturers of diagnostics, life-sciences, biopharma products and International marketing services companies. Biogenuix's portfolio includes a range of Specialized Diagnostic products as well as a large portfolio of antibodies, peptides,IHC slides, si-RNA's, microarray substrates and other regents. Biogenuix offers the most comprehensive range of Transplant Diagnostics products in India and exclusively represents One Lambda Inc, the pioneers and global leaders in transplant diagnostics and research products.

About Gene Express, Inc.

Gene Express, Inc. is a molecular diagnostic company that integrates personalized medicine into clinical care by enabling the generation of standardized, comparable and quality controlled data for molecular diagnostic testing. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcription Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, clinical biopsies and blood is being used to develop proprietary molecular diagnostics and to develop the molecular diagnostics capabilities of other companies. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at www.geneexpressinc.com.

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.